Welcome to the Healthspan Insider Research Roundup where Mark reviews the latest science on longevity and optimisation. Here are his top three studies of interest for this edition.
Watch the video below for Mark’s overview, including actionable takeaways for optimisers.
This month’s top 3 optimisation and longevity studies
Below is Mark’s written commentary on the top 3 studies of interest this month, including actionable takeaways for optimisers.
1. Why higher intensity may beat Zone 2 for health
Zone 2 has been popularised as the go-to for mitochondrial and cardiovascular benefits. But as I explain in the video, a Sports Medicine review found the evidence just isn’t strong enough to support Zone 2 as a standalone strategy for mitochondrial health or fatty acid oxidation.
That doesn’t mean Zone 2 isn’t helpful – it can be a good starting point for people who are unfit. However, the review makes it clear that the real long-term benefits come from progressing to higher intensity training, alongside strength and resistance work.
For the general population, the takeaway message is that regular exercise, combining cardio, strength and resistance, and higher intensity exercise will provide more benefits than zone 2 alone.
Key takeaways
- Mix in higher intensities for heart and metabolic health: If you already meet weekly activity goals, add short bursts of vigorous exercise to better boost fitness, glucose control, and resilience. If time is limited, ask your practitioner or trainer how to do this safely
- Use Zone 2 strategically for fat adaptation in beginners: Zone 2 helps new or low-fitness individuals build fat-burning efficiency and sustain activity. Progressively add intensity over time to keep improving health markers and avoid plateaus
- Match training to your current capacity: Zone 2 varies widely between people. Use personalised testing or validated cues (e.g., talk test, lactate measures) instead of generic heart-rate charts to ensure the right training benefits
2. Gut bacteria linked to lifespan and ageing
A GeroScience study explored causal links between gut microbes and longevity. They found 12 microbes tied to ageing – some protective, some harmful. For instance, Streptococcus was linked to faster ageing, while Akkermansia and Blautia were consistently linked to longer lifespan.
What stood out to me was the finding that a single immune protein (CD28) partly mediated Streptococcus’ impact on ageing. That strengthens the case for a gut–brain–immune pathway influencing longevity.
Whilst a lot of the research is still new and exploratory, there is little doubt that the gut microbiome plays a significant role in human healthspan and lifespan. Simple and accessible stool tests using metagenomic sequencing help provide insight into an individual’s unique microbiome, informing targeted strategies for improving its impact on individual health.
Key takeaways
- Maintain Streptococcus balance: High Streptococcus may drive inflammation and shorten lifespan. If testing shows overgrowth, work with your practitioner on diet, probiotics, or antimicrobials to restore balance
- Support Akkermansia and Blautia: These microbes are tied to longevity. Feed them with fibre-rich plants, polyphenols, and possibly targeted probiotics to strengthen metabolism, gut barrier, and resilience
- Address gut–brain inflammation: Imbalance can trigger brain inflammation via the CD28 pathway. Anti-inflammatory diets, omega-3s, and stress reduction help, while testing guides personalised care
3. Why most cholesterol drugs won’t reduce Lp(a)
Elevated Lp(a) is an independent cardiovascular risk factor, but most doctors still reach for statins. A new Atherosclerosis review reinforces what I often see in practice: statins and many standard lipid drugs simply don’t touch Lp(a).
The therapies that do help include PCSK9 inhibitors, CETP inhibitors, and niacin. But each comes with pros and cons – and until more effective therapies are widely available, the best strategy remains to implement effective diet, exercise and lifestyle strategies to promote cardiovascular health, combined with targeted supplementation, and potentially, more appropriate pharmacological interventions.
Key takeaways
- Focus on therapies that lower Lp(a): If levels are high, ask your practitioner about PCSK9 inhibitors or inclisiran – especially if LDL-C lowering is also needed. Consider benefits alongside cost, access, and risk profile
- Niacin has pros and cons: It can lower Lp(a), but evidence for heart benefit is unclear, and side effects (flushing, liver strain, glucose changes) are common. Use only if tolerated and monitored
- Don’t rely on standard lipid drugs for Lp(a) lowering: Statins and ezetimibe don’t lower Lp(a), though they still cut risk by lowering LDL-C. Pair LDL-C optimisation with targeted Lp(a) therapies where possible
Other research of interest this month
Beyond Mark’s top three picks, here are more highlights we’ve included in this month’s Healthspan Insider.
Akkermansia postbiotics for skin repair & anti-ageing
Postbiotics from Akkermansia muciniphila improved skin hydration, collagen, and repair after UV exposure in cell and human studies.
Key takeaways
- Explore topical postbiotics for sensitive skin: Lysates from A. muciniphila may improve hydration and barrier strength. Start with evidence-based products and introduce gently to assess tolerance
- Protect skin from sun-related ageing: UV drives inflammation and barrier damage. Daily sunscreen plus antioxidants and postbiotics can support firmer, calmer skin, especially with high sun exposure
- Choose strain-specific, tested products: Not all postbiotics act the same. Look for human-tested formulations that list the strain and dose to ensure safety and effectiveness
Advances in replacement therapies
Emerging approaches like cell therapy, 3D bioprinting, xenotransplantation, and brain–machine interfaces are advancing the possibility of organ or system replacement to extend healthspan.
Key takeaway
- Plan for minimally invasive recovery: In older adults, surgical stress matters. Choose less invasive or newer replacement techniques to reduce inflammation, protect cognition, and speed recovery
Psilocybin extends cell lifespan
In lab and animal studies, psilocybin preserved telomeres, reduced oxidative stress, and extended fibroblast lifespan.
Key takeaway
- Psilocybin and healthy ageing – future potential: Early animal research suggests psilocybin may influence longevity, even later in life. For now, track new studies, explore legal therapeutic options, and discuss suitability with your practitioner
Gene editing for long-term GLP-1 release
In obese, pre-diabetic mice, one-time CRISPR editing enabled sustained GLP-1 production from the liver, improving glucose control for 6+ months.
Key takeaways
- Optimise GLP-1 pathways: For weight or pre-diabetes, ask your practitioner about nutrition, medications, or therapies that enhance GLP-1 signalling to curb appetite and stabilise blood sugar
- Support liver health as a hormone hub: The liver drives long-term peptide release. Protect it with an anti-inflammatory diet, stable blood sugar, and reduced toxin exposure to sustain metabolic balance
- Plan for long-term strategies to prevent relapse: A key benefit here was the prevention of weight regain after treatment stopped. In practice, adopting foundational lifestyle measures – balanced diet, regular activity, stress management – can help maintain results from any metabolic intervention and reduce the need for frequent medication adjustments
Thanks for reading this edition of the Healthspan Insider. We hope August’s insights support you on your optimisation journey.
Not yet subscribed? Join today to get Mark’s monthly takeaways delivered direct to your inbox – just complete the form on this page.
